EQT Corporation Securities Litigation (2021)

Natural-gas producer EQT drills for gas primarily in Pennsylvania, West Virginia and Ohio, utilizing the practice of “fracking” to extract gas from shale deposits.  EQT sought to acquire a rival company, Rice by way of a merger (the “Rice Acquisition” or “Acquisition”). Rice held various tracts of lands adjacent to EQT’s property.  The Rice Acquisition, announced on June 19,  2017,  would  expand  the  total  acreage  available  for  EQT’s  drilling  and  fracking.

See Case Details »

AcelRx Pharmaceuticals, Inc. Securities Litigation (2021)

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-tosevere acute pain. DSUVIA is a potent opioid painkiller that is of particular use in certain special circumstances where adult patients may not be able to swallow oral medication and where access to intravenous pain relief is not possible.

See Case Details »

RLX Technology Inc. : American Depositary Shares Securities Litigation

RLX Technology Inc. manufactures and sells vaping products in China.

See Case Details »

Frequency Therapeutics, Inc. Securities Litigation

Frequency Therapeutics, Inc. is primarily focused on the development and commercialization of a hearing loss treatment called “FX-322.”

See Case Details »

GW Pharmaceuticals, PLC : American Depositary Shares Securities Litigation (2021)

GW Pharmaceuticals, PLC is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from their proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. The Company has two primary, more developed products: Epidiolex and Nabiximols (Sativex). GW also has a deep pipeline of additional cannabinoid product candidates and novel compounds, including compounds in Phase 1, Phase 2, and Phase 3 trials.

See Case Details »